Levodopa
- Part D specialty tier in 82% of formularies (2026Q3)
- Inbrija
Therapy management checklist
Screening, baseline and ongoing monitoring with the label's stated frequency, hold and discontinue criteria, and counseling points, each quoted from the FDA label.
Loading the therapy management checklist…
Storage and cold chain
Levodopa: storage and handling
- Freezing
- Not addressed
- Room temperature
- at or below 25°C (77°F)
Label statement
Store the inhaler and capsules in a dry place at room temperature between 68°F to 77°F (20°C to 25°C).
- Back into the refrigerator
- Not addressed
- Light
- Not addressed
- Shaking
- Not addressed
All storage statements on the label (5)
- Store in a dry place between 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F).
- INBRIJA capsules should always be stored in the blister packaging and only removed immediately before use.
- INBRIJA capsules should not be stored inside the INBRIJA inhaler.
- Store the inhaler and capsules in a dry place at room temperature between 68°F to 77°F (20°C to 25°C).
- Do not store capsules inside the inhaler for a future dose.
FDA label version 2, effective July 20, 2026. DailyMed
Dosing and titration calendar
Built only from the schedules the label states (loading, titration, day schedules, cycles and weight bands). Steps the label states in words the calendar cannot place are shown, not guessed.
Loading dosing schedules…
Medicare Part D coverage
5,496 Part D plans, CMS formulary files 2026Q3. Look up tier, PA, step therapy and quantity limits by plan
Patient assistance
No manufacturer program page is listed for this drug yet.
Independent foundations and the full directory (checked 2026-11-06). Eligibility and amounts are set by each program; open its page for them.
For licensed clinicians. Use with clinical judgment. Statements are quoted from the FDA label; confirm against the label for the product you are using.